Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Venous thromboembolism risk in patients with hormone receptor‑positive her2‑negative metastatic breast cancer treated with CDK 4/6 inhibitors

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: PPM-002
  • By: SERTIć, Miranda ()
  • Co-author(s): MPharm Matea Baković (PrimeVigilance d.o.o., Zagreb, Croatia)
    Prof. Maja Ortner Hadžiabdić, Centre for Applied Pharmacy (University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia)
    PhD Tajana Silovski (University Hospital Centre Zagreb, Zagreb, Croatia)
    Prof Miranda Sertić, Associate Professor (University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia)
  • Abstract:

    Background: Breast cancer is the most common cancer diagnosed among women worldwide. More than 70% of breast cancers are hormone receptor (HR)-positive, for which endocrine therapy is the preferred initial treatment. Since their first approval in 2015, cyclin-dependent kinase 4/6 inhibitors (CDKIs) are widely used in clinical practice for treating ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses